Correlation of \textit{EGFR} or \textit{KRAS} mutation status with \(^{18}\)F-FDG uptake on PET-CT scan in lung adenocarcinoma

Kazuya Takamochi\(^1\)\(^*\), Kaoru Mogushi\(^2\), Hideya Kawaji\(^3\)\(^,4\), Kota Imashimizu\(^1\), Mariko Fukui\(^1\), Shiaki Oh\(^1\), Masayoshi Itoh\(^3\), Yoshihide Hayashizaki\(^2\), Weijey Ko\(^5\), Masao Akeboshi\(^5\), Kenji Suzuki\(^1\)

1 Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan, 2 Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Tokyo, Japan, 3 Preventive Medicine and Applied Genomics Unit, RIKEN Advanced Center for Computing and Communication, Yokohama, Kanagawa, Japan, 4 RIKEN Preventive Medicine and Diagnosis Innovation Program, Wako, Saitama, Japan, 5 Diagnostic Imaging Center, Yotsuya Medical Cube, Tokyo, Japan

* ktakamo@juntendo.ac.jp

Abstract

Background
\(^{18}\)F-fluoro-2-deoxy-glucose (\(^{18}\)F-FDG) positron emission tomography (PET) is a functional imaging modality based on glucose metabolism. The correlation between \textit{EGFR} or \textit{KRAS} mutation status and the standardized uptake value (SUV) of \(^{18}\)F-FDG PET scanning has not been fully elucidated.

Methods
Correlations between \textit{EGFR} or \textit{KRAS} mutation status and clinicopathological factors including SUV\(_{\text{max}}\) were statistically analyzed in 734 surgically resected lung adenocarcinoma patients. Molecular causal relationships between \textit{EGFR} or \textit{KRAS} mutation status and glucose metabolism were then elucidated in 62 lung adenocarcinomas using cap analysis of gene expression (CAGE), a method to determine and quantify the transcription initiation activities of mRNA across the genome.

Results
\textit{EGFR} and \textit{KRAS} mutations were detected in 334 (46\%) and 83 (11\%) of the 734 lung adenocarcinomas, respectively. The remaining 317 (43\%) patients had wild-type tumors for both genes. \textit{EGFR} mutations were more frequent in tumors with lower SUV\(_{\text{max}}\). In contrast, no relationship was noted between \textit{KRAS} mutation status and SUV\(_{\text{max}}\). CAGE revealed that 4 genes associated with glucose metabolism (GPI, G6PD, PKM2, and GAPDH) and 5 associated with the cell cycle (ANLN, PTTG1, CIT, KPNA2, and CDC25A) were positively correlated with SUV\(_{\text{max}}\), although expression levels were lower in \textit{EGFR}-mutated than in wild-type tumors. No similar relationships were noted with \textit{KRAS} mutations.
Conclusions

EGFR-mutated adenocarcinomas are biologically indolent with potentially lower levels of glucose metabolism than wild-type tumors. Several genes associated with glucose metabolism and the cell cycle were specifically down-regulated in EGFR-mutated adenocarcinomas.

Introduction

Recently, driver oncogene mutations are being discovered at a rapid pace. Therapeutic agents targeting some of these driver oncogenes have been successfully developed. The somatic mutations in epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are the most frequently found in lung adenocarcinomas. The presence of an EGFR mutation is the most important predictor of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) [1, 2]. In contrast, KRAS mutations are a useful biomarker of EGFR-TKI resistance [3]. It is therefore important to understand the occurrence of EGFR and KRAS mutations when deciding the initial treatment for lung cancer. However, to obtain sufficient tumor tissue to perform the genetic analyses is frequently difficult in lung cancer patients, especially those with unresectable disease. Non-invasive methods to estimate the probability of the EGFR/KRAS mutation status are helpful in clinical practice.

18F-fluoro-2-deoxy-glucose (18F-FDG) positron emission tomography (PET), a functional imaging modality based on glucose metabolism, has become a standard tool for the diagnosis, initial staging, and evaluation of treatment efficacy in lung cancer [4]. High 18F-FDG uptake reflects both the increased glucose metabolism and proliferative activity of tumor cells [5, 6]. EGFR mutations activate the EGFR-signaling pathway, inhibit apoptosis, and increase cell proliferation, angiogenesis and metastatic potential [7]. KRAS plays a key role in the downstream signaling RAS/MAPK pathway of EGFR and other growth factor receptors [7]. Point mutations of KRAS also play a critical role in cancer cell growth. Therefore, we hypothesized that there is a causal relationship between increased glucose metabolism and EGFR or KRAS mutation.

The emergence of next-generation sequencing technologies has enabled a wide range of protocols for more comprehensive and accurate genome-wide analysis. Among these, cap analysis gene expression (CAGE) is a genome-wide approach forming a comprehensive profile of the transcriptome by sequencing only the 5'-ends of capped RNAs [8]. Profiles represent promoter activities based on the frequencies of transcription starting sites (TSSs). CAGE has been used in genome-wide studies such as the ENCODE project [9] and FANTOM5 project [10–12]. Given that the transcriptome represents the molecular basis underlying cellular characteristics, we recently applied CAGE to the study of biomarkers to discriminate distinct types of lung cancer [13]. To date, however, CAGE has not been used to study glucose metabolism in tumor cells.

Using transcriptome data from lung adenocarcinomas that monitor expression levels of genes that play important and specific roles in glucose metabolism, we investigated possible correlations between the standardized uptake value (SUV) of 18F-FDG PET and EGFR or KRAS mutation status in lung adenocarcinoma. Furthermore, we also investigated the specific molecular background of glucose metabolism in EGFR- or KRAS-mutated lung adenocarcinoma.

Materials and methods

Patients

Between February 2009 and May 2014, 1414 patients with primary lung cancers, including 1062 with adenocarcinomas, underwent pulmonary resection at our institution. Among these,
we retrospectively reviewed 734 adenocarcinoma patients who underwent $^{18}$F-FDG PET-CT scanning within 2 months before surgery and whose surgically resected specimens were examined for EGFR and KRAS mutations. Patients who underwent induction chemotherapy and/or radiotherapy were excluded from this study. Patients were classified into three groups according to the mutation status of the tumors, namely EGFR mutation-positive (EGFR m$^+$), KRAS mutation-positive (KRAS m$^+$), and wild-type (WT) for both genes. Clinical characteristics such as age, gender, smoking status, preoperative serum carcinoembryonic antigen (CEA) level and SUV$_{\text{max}}$ and pathological findings such as tumor size, nodal status, lymphatic permeation and vascular invasion of EGFR m$^+$ and KRAS m$^+$ tumors were compared to those of WT tumors.

This study was performed using surgical specimens in the tissue bank at our department, which was established with the approval of the institutional review board (IRB) of Juntendo University School of Medicine. Written consent was obtained from all patients prior to surgery for the procurement of tissue for the research purposes. The IRB approved the use of specimens stored in the tissue bank without obtaining new informed consent and deemed that the contents of this study were ethically acceptable.

$^{18}$F-FDG PET-CT scanning

As detailed previously [14], PET-CT scan was carried out with a Discovery ST PET/CT scanner (GE Medical Systems; Waukesha, WI, USA) at the Yotsuya Medical Cube (Tokyo Japan). Two experienced nuclear medicine radiologists (W. K. and M. A.) evaluated the PET-CT images, side by side, and reached a consensus on the findings.

Mutation analyses for EGFR and KRAS

Genomic DNA was extracted from frozen lung cancer tissues sampled from surgically resected specimens. EGFR mutations were analyzed using the peptide nucleic acid-locked nucleic acid polymerase chain reaction (PCR) clamp method [15], and KRAS mutations using the peptide nucleic acid-mediated PCR clamping method [16].

Statistical analysis of the correlations between EGFR or KRAS mutation status and clinicopathological factors

The Steel-Dwass test was used to compare SUV$_{\text{max}}$ among multiple groups based on EGFR and KRAS mutation patterns. Receiver operating characteristic (ROC) curves were generated to obtain a cut-off for SUV$_{\text{max}}$ of the primary tumor which maximizes the sum of sensitivity and specificity for predicting EGFR or KRAS mutation status. Correlations between EGFR or KRAS mutation status and clinicopathological factors were evaluated. Univariate analyses between SUV$_{\text{max}}$ and each clinicopathological factor were performed by a logistic regression model. All of the variables identified to be significant in the univariate analyses were subsequently entered into the multivariate analyses using a bidirectional (i.e., forward and backward) step-wise logistic regression model. A $P$-value of $< 0.05$ was considered statistically significant. All statistical analyses were performed using the R statistical software package (version 3.0.2, http://www.r-project.org/).

CAGE data

CAGE data generated using the previously described protocol [17] were obtained from a previous study [13]. In brief, double-stranded RNA/cDNA produced by reverse transcription from total RNA extracts was purified, oxidized with sodium periodate, and biotinylated with biotin hydrazide. The single-stranded cDNA was recovered after digestion of the single-stranded
RNA with RNase I, and ligated with 3'-end and 5'-end adaptors specific to the samples. Double-stranded cDNAs were synthesized and mixed for sequencing in one lane of an Illumina HiSeq2500 sequencer (Illumina; San Diego, CA, USA). The CAGE reads were aligned to the reference genome (hg19) with high mapping quality of ≥ 20.

Differential and correlation analysis using the CAGE data

The aligned CAGE reads were counted in each region of the FANTOM5 robust peaks [11], a reference set of TSS regions, as raw signals for the promoter activities. Expression (activity) levels of individual promoters were quantified as counts per million (CPM) after normalization by the relative log expression method [18], and subjected to differential analysis using edgeR (version 3.2.4) [19] in R/Bioconductor [20]. Associations between expression levels and SUV\textsubscript{max} and their statistical significance were assessed by Spearman's rank correlation. Only results with a false discovery rate (FDR) less than 1% were considered statistically significant, in both the differential and correlation analyses.

Results

Patient characteristics and \textit{EGFR} and \textit{KRAS} mutation status

Patient characteristics are summarized in Table 1. Of 734 patients, 367 (50%) were male and 367 (50%) were female. Median age at the time of the operation was 68 years (range, 27–89 years). A total of 363 of 734 (49%) patients were smokers (pack-years > 5) and 371 (51%) were non-smokers (pack-years ≤ 5).

Of the 734 lung adenocarcinomas, \textit{EGFR} and \textit{KRAS} mutations were detected in 334 (46%) and 83 (11%), respectively. The \textit{EGFR} mutation spectra were distributed as follows. The point mutation L858R in exon 21 and deletions in exon 19 were detected in 194 and 120 tumors, respectively, which together accounted for 94% of all \textit{EGFR} alterations. The remaining 6% of the minor \textit{EGFR} mutations were exon 18 G719A in 8 tumors, exon 18 G719S in 5, exon 18 G719C in 2 and exon 21 L861Q in 3. Double mutations were found in 2 tumors; 1 harbored exon 21 L861Q and exon 20 T790M and the other had exon 18 G719A and exon 20 T790M, simultaneously. With regard to \textit{KRAS}, a point mutation in codon 12 was found in 81 (98%) tumors, and a point mutation in codon 13 in 2 (2%). G to T, or G to C transversions were found in 60 (72%) tumors, and G to A transition in 23 (28%). \textit{EGFR} and \textit{KRAS} mutations were mutually exclusive.

The median SUV\textsubscript{max} of all primary tumors was 2.7 (range, 0–33.2). Median SUV\textsubscript{max} in the \textit{EGFR} m\textsuperscript{+} group, \textit{KRAS} m\textsuperscript{+} group, and WT group were 2.1 (range, 0–23), 3.0 (range, 0–23.5), and 3.9 (range, 0–33.2), respectively. SUV\textsubscript{max} of \textit{EGFR} m\textsuperscript{+} tumors was significantly lower than that of WT and \textit{KRAS} m\textsuperscript{+} tumors (Fig 1A). SUV\textsubscript{max} of tumors with exon 21 L858R or exon 19 deletions was significantly lower than that of WT tumors. However, no significant differences were noted in SUV\textsubscript{max} between tumors with minor mutations and WT tumors (Fig 1B). The SUV\textsubscript{max} of \textit{KRAS} m\textsuperscript{+} tumors did not significantly differ from that of WT tumors (Fig 1A). No significant differences were found in SUV\textsubscript{max} between tumors with any \textit{KRAS} mutation spectrum (G to T/G to C transversions or G to A transition) and WT tumors (Fig 1C).

ROC curve analyses of the cut-off values of SUV\textsubscript{max} for the prediction of \textit{EGFR} or \textit{KRAS} mutations

Next, we evaluated the prediction of \textit{EGFR} or \textit{KRAS} mutation using SUV\textsubscript{max}. A cut-off value of SUV\textsubscript{max} ≤ 2.69 provided the highest area under the curve (AUC; 0.610) for predicting \textit{EGFR} mutation, while SUV\textsubscript{max} ≤ 3.40 provided the highest AUC (0.536) for \textit{KRAS} mutation (Fig 2). Using these cut-off values, parameters for the prediction of \textit{EGFR} mutations were
sensitivity, 60%; specificity, 61%; accuracy, 60%; positive predictive value (PPV), 62%; and negative predictive value (NPV), 59%; and parameters for the prediction of KRAS mutations were sensitivity, 54%; specificity, 54%; accuracy, 54%; PPV, 23%; and NPV, 82%.

Table 1. Clinical characteristics of patients.

| Characteristic | n (%) |
|---------------|-------|
| Age (years)   |       |
| ≤ 65          | 309 (42) |
| > 65          | 425 (58) |
| Sex           |       |
| Male          | 367 (50) |
| Female        | 367 (50) |
| Smoking       |       |
| ≤ 5 PY        | 371 (51) |
| > 5 PY        | 363 (49) |
| Serum CEA level |     |
| Normal        | 386 (53) |
| Elevated      | 348 (47) |
| Tumor size    |       |
| < 30 mm       | 514 (70) |
| > 30 mm       | 220 (30) |
| Pathological stage |     |
| IA/IB         | 410/123 |
| IIA/IIIB      | 40/36  |
| IIIA/IIIB     | 99/8   |
| IV            | 18     |
| Pathological nodal status |   |
| N0            | 578 (79) |
| N1 / N2       | 156 (21) |
| Lymphatic permeation |     |
| Negative      | 539 (73) |
| Positive      | 195 (27) |
| Vascular invasion |     |
| Negative      | 514 (70) |
| Positive      | 220 (30) |
| SUV_{max}     | Median (range) | 2.7 (0–33.2) |
| EGFR mutation |       |
| Negative      | 400 (54) |
| Positive      | 334 (46) |
| exon 21 L858R | 194     |
| exon 19 deletions | 120   |
| minor mutations | 20 |
| KRAS mutation |       |
| Negative      | 651 (89) |
| Positive      | 83 (11)  |
| G to T/G to C | 60       |
| G to A        | 23       |

PY = pack years.

https://doi.org/10.1371/journal.pone.0175622.t001
Correlation of *EGFR* or *KRAS* mutation status with FDG uptake in lung adenocarcinoma

Fig 1. Correlations between SUV$_{\text{max}}$ of primary tumors and *EGFR* and *KRAS* mutation status. (A) Box plot of SUV$_{\text{max}}$ of primary tumors according to *EGFR* and *KRAS* mutation status, (B) Box plot of SUV$_{\text{max}}$ of primary tumors according to *EGFR* mutation spectra, (C) Box plot of SUV$_{\text{max}}$ of primary tumors according to *KRAS* mutation spectra.

https://doi.org/10.1371/journal.pone.0175622.g001

Fig 2. Cut-off values of SUV$_{\text{max}}$ in prediction of *EGFR* and *KRAS* mutation. (A) *EGFR* mutation, (B) *KRAS* mutation.

https://doi.org/10.1371/journal.pone.0175622.g002
Univariate and multivariate analysis of the predictors of *EGFR* or *KRAS* mutations

On univariate analysis, *EGFR* mutations were more frequent in females, non-smokers, patients with normal CEA levels, tumors without lymph node involvement or blood vessel invasion, and tumors with lower \( \text{SUV}_{\text{max}} \). On multivariate analysis, significant predictors of *EGFR* mutation were smoking status and \( \text{SUV}_{\text{max}} \) (Table 2). The probability of *EGFR* mutation was inversely correlated with \( \text{SUV}_{\text{max}} \). Univariate analyses showed that *KRAS* mutations were more frequent in males and smokers. On multivariate analysis, the only significant predictor of *KRAS* mutation was smoking history (Table 3). No relationship was found between the *KRAS* mutation status and \( \text{SUV}_{\text{max}} \). The predictability of *EGFR* mutation status was compared between combinations of well-established clinical factors with or without \( \text{SUV}_{\text{max}} \) (Table 4). PPV of *EGFR* mutation status was increased by adding \( \text{SUV}_{\text{max}} \) to gender and smoking status.

CAGE for the molecular background of glucose metabolism in *EGFR* or *KRAS* mutated lung adenocarcinoma

Further, we examined expression levels of genes based on the CAGE results (Takamochi et al., submitted), in particular those related to glucose metabolism and the cell cycle, in association

### Table 2. Univariate and multivariate analysis of predictors of *EGFR* mutation.

| Characteristic                  | WT (n = 317) | EGFR m⁺ | Univariate analysis | Multivariate analysis |
|--------------------------------|--------------|---------|--------------------|----------------------|
|                                |              |         | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
| Age (years)                    |              |         |                    |         |                     |         |
| ≤ 65                           | 143          | 137     | 1                  |         |                     |         |
| > 65                           | 174          | 197     | 1.182 (0.866–1.613) | 0.292 |                     |         |
| Sex                            |              |         |                    |         |                     |         |
| Female                         | 136          | 210     | 1                  |         |                     |         |
| Male                           | 181          | 124     | 0.444 (0.323–0.607) | < 0.001 |                     |         |
| Smoking                        |              |         |                    |         |                     |         |
| ≤ 5 PY                         | 131          | 229     | 1                  |         |                     |         |
| > 5 PY                         | 186          | 105     | 0.323 (0.234–0.444) | < 0.001 | 0.357 (0.256–0.494) | < 0.001 |
| Serum CEA level                |              |         |                    |         |                     |         |
| Normal                         | 157          | 197     | 1                  |         |                     |         |
| Elevated                       | 160          | 137     | 0.682 (0.500–0.930) | 0.016 |                     |         |
| Tumor size                     |              |         |                    |         |                     |         |
| < 30 mm                        | 218          | 243     | 1                  |         |                     |         |
| ≥ 30 mm                        | 99           | 91      | 0.825 (0.587–1.156) | 0.264 |                     |         |
| Pathological nodal status      |              |         |                    |         |                     |         |
| N0                             | 232          | 277     | 1                  |         |                     |         |
| N1 / N2                        | 85           | 57      | 0.562 (0.383–0.818) | 0.003 |                     |         |
| Lymphatic permeation           |              |         |                    |         |                     |         |
| Negative                       | 221          | 253     | 1                  |         |                     |         |
| Positive                       | 96           | 81      | 0.737 (0.521–1.041) | 0.084 |                     |         |
| Vascular invasion              |              |         |                    |         |                     |         |
| Negative                       | 204          | 251     | 1                  |         |                     |         |
| Positive                       | 113          | 83      | 0.597 (0.425–0.836) | 0.003 |                     |         |
| \( \text{SUV}_{\text{max}} \) |              |         |                    |         |                     |         |
| ≤ 2.69                         | 124          | 200     | 1                  |         |                     |         |
| > 2.69                         | 193          | 134     | 1                  |         |                     |         |

WT = wild-type; m⁺ = mutation-positive; PY = pack years.

https://doi.org/10.1371/journal.pone.0175622.t002
with $SUV_{\text{max}}$. We manually selected 7 genes associated with glucose metabolism: class I glucose transporters (GLUT1, GLUT2, GLUT3, GLUT4), hexokinase-II (HK-II), hypoxia-inducible factor-1 alpha (HIF-1$\alpha$), and carbonic anhydrase IX (CAIX). Of these, 4 genes (GLUT1, 

Table 3. Univariate and multivariate analysis of predictors of KRAS mutation.

| Characteristic          | WT (n = 317) | KRAS m* (n = 83) | Univariate analysis | Multivariate analysis |
|-------------------------|--------------|------------------|---------------------|-----------------------|
| Age (years)             |              |                  |                     |                       |
| $\leq 65$               | 143          | 29               | 1                   |                       |
| $> 65$                  | 174          | 54               | 1.530 (0.932–2.554) | 0.097                 |
| Sex                     |              |                  |                     |                       |
| Female                  | 136          | 21               | 1                   |                       |
| Male                    | 181          | 62               | 2.218 (1.308–3.890) | 0.004                 |
| Smoking                 |              |                  |                     |                       |
| $\leq 5$ PY             | 131          | 12               | 1                   |                       |
| $> 5$ PY                | 186          | 71               | 4.167 (2.248–8.359) | $< 0.001$             |
| Serum CEA level         |              |                  |                     |                       |
| Normal                  | 157          | 32               | 1                   |                       |
| Elevated                | 160          | 51               | 1.564 (0.959–2.581) | 0.076                 |
| Tumor size              |              |                  |                     |                       |
| $< 30$ mm               | 218          | 53               | 1                   |                       |
| $\geq 30$ mm            | 99           | 30               | 1.246 (0.745–2.059) | 0.394                 |
| Pathological nodal status |             |                  |                     |                       |
| N0                      | 232          | 69               | 1                   |                       |
| N1 / N2                 | 85           | 14               | 0.554 (0.286–1.009) | 0.064                 |
| Lymphatic permeation    |              |                  |                     |                       |
| Negative                | 221          | 65               | 1                   |                       |
| Positive                | 96           | 18               | 0.637 (0.351–1.112) | 0.124                 |
| Vascular invasion       |              |                  |                     |                       |
| Negative                | 204          | 59               | 1                   |                       |
| Positive                | 113          | 24               | 0.734 (0.427–1.231) | 0.251                 |
| SUV max                 |              |                  |                     |                       |
| $\leq 3.4$              | 147          | 45               | 1                   |                       |
| $> 3.4$                 | 170          | 38               | 0.730 (0.448–1.185) | 0.204                 |

WT = wild-type; m* = mutation-positive; PY = pack years.

https://doi.org/10.1371/journal.pone.0175622.t003

Table 4. Predictability of the EGFR mutation status by the combinations of well-established clinical factors with or without SUV$_{\text{max}}$.

| Clinical predictors | EGFR mutation status | Sensitivity | Specificity | PPV | NPV | Accuracy |
|---------------------|----------------------|-------------|-------------|-----|-----|----------|
|                     | Positive | Negative |                  |     |     |          |
| Female & Non-smoker * Yes | 182      | 115      | 54%          | 71% | 61% | 65%      | 64%      |
|                     | No       | 152      | 285          |     |     |          |
| Non-smoker & SUV$_{\text{max}}$ $\leq 2.69$ Yes | 131      | 83       | 39%          | 79% | 61% | 61%      | 61%      |
|                     | No       | 203      | 317          |     |     |          |
| Female & Non-smoker & SUV$_{\text{max}}$ $\leq 2.69$ Yes | 110      | 66       | 33%          | 84% | 63% | 60%      | 60%      |
|                     | No       | 224      | 334          |     |     |          |

* means pack-years $\leq 5$.

PPV = positive predictive value; NPV = negative predictive value.

https://doi.org/10.1371/journal.pone.0175622.t004
Correlation of EGFR or KRAS mutation status with FDG uptake in lung adenocarcinoma

Spearman's correlation 0.52; P value 1.62e-05

expression level of GLUT1 (cpm + 1)

Spearman's correlation 0.17; P value 1.76e-01

expression level of HK-II (cpm + 1)

Spearman's correlation 0.40; P value 1.41e-03

expression level of CAIX (cpm + 1)

Spearman's correlation 0.62; P value 5.76e-08

expression level of HIF-1α (cpm + 1)

Spearman's correlation 0.41; P value 1.07e-03

expression level of VEGFA (cpm + 1)

Spearman's correlation -0.44; P value 3.61e-04

expression level of BCL2 (cpm + 1)
HK-II, HIF-1α, and CAIX) showed positive correlations between their expression levels monitored by CAGE with SUV$_{\text{max}}$ across 62 lung adenocarcinomas (Fig 3). Next, we selected 5 genes associated with cell growth: TP53, CCND1, BCL2, vascular endothelial growth factor (VEGF), and MKI67. Of these, expression of VEGF showed a positive correlation with SUV$_{\text{max}}$, while BCL2 showed an inverse correlation with SUV$_{\text{max}}$ (Fig 3).

We expanded this expression analysis to examine genes involved in the 2 pathways. Among genes whose promoters were more significantly down-regulated in EGFR m$^+$ tumors than WT tumors (FDR < 1%), we found that both glucose metabolism-related and cell cycle-related genes were enriched (P value < 5.2e-18 and 0.02, with GO term enrichment analysis with DAVID) [21, 22]. Of these, 4 genes associated with glucose metabolism (GPI, G6PD, PKM2, and GAPDH) and 5 genes associated with the cell cycle (ANLN, PTTG1, CIT, KPNA2, and CDC25A) showed a positive correlation between expression and SUV$_{\text{max}}$. (FDR < 1%; Fig 4).

Notably, none of the genes down-regulated in KRAS m$^+$ tumors showed significant correlation with SUV$_{\text{max}}$.

Discussion

In this study, we found that the probability of EGFR mutation in lung adenocarcinoma was inversely correlated with SUV$_{\text{max}}$. In contrast, the probability of KRAS mutation was not correlated with SUV$_{\text{max}}$. Further, several genes associated with glucose metabolism or the cell cycle were specifically down-regulated in EGFR m$^+$ adenocarcinomas. These findings suggest that EGFR m$^+$ adenocarcinomas are biologically indolent with potentially lower levels of glucose metabolism than wild-type tumors.

To our knowledge, this is the largest study to evaluate the correlations between $^{18}$F-FDG uptake and EGFR mutation status in lung cancer, and the first to investigate the correlation between the $^{18}$F-FDG uptake and KRAS mutation status. The 4 retrospective studies that previously investigated the correlation between the $^{18}$F-FDG uptake and EGFR mutation status in lung cancer [23–26] reported contradictory findings (Table 4). In their multivariate analysis, Huang et al.[23] and Ko et al.[26] showed that a higher SUV$_{\text{max}}$ was a significant predictor of EGFR mutation, whereas Na et al.[25] and Mak et al.[24] reported that a lower SUV$_{\text{max}}$ of the primary tumor was predictive of EGFR mutation. Our findings are compatible with those of the latter groups [24, 25]. These conflicting results may have resulted from differences in the ethnic background or the small size of the study populations (Table 5).

Consistent with numerous previous reports [27–29], EGFR mutations in the present study were more frequent in females and never-smokers. In addition, a higher probability of EGFR mutation was observed in tumors without lymph node involvement or blood vessel invasion and in those with a lower SUV$_{\text{max}}$. Higashi et al.[30] reported that the prevalence rates of lymphatic permeation and lymph node involvement were lower in primary tumors with low $^{18}$F-FDG uptake than those with a higher $^{18}$F-FDG uptake. These findings suggest that EGFR m$^+$ adenocarcinomas are biologically indolent with potentially lower levels of glucose metabolism.

Although many factors have been reported to influence $^{18}$F-FDG uptake, the precise biological mechanism by which $^{18}$F-FDG accumulates in malignant cells remains to be clarified. In 1985, Mueckler et al.[31] initially reported that facilitative glucose transport across the plasma
Correlation of EGFR or KRAS mutation status with FDG uptake in lung adenocarcinoma

A) Spearman's correlation 0.50; P value 6.77e-05

B) Spearman's correlation 0.55; P value 1.93e-05

C) Spearman's correlation 0.42; P value 7.48e-07

D) Spearman's correlation 0.66; P value 1.35e-05

E) Spearman's correlation 0.52; P value 7.66e-05

F) Spearman's correlation 0.64; P value 2.91e-05

G) Spearman's correlation 0.53; P value 5.30e-05

H) Spearman's correlation 0.52; P value 7.49e-05

I) Spearman's correlation 0.52; P value 6.24e-05
membrane was mediated by a family of structurally related proteins known as facilitated diffuse GLUTs. Among the 14 currently known GLUT isoforms [32], the overexpression of GLUT-1 has been shown to be most closely related to $^{18}$F-FDG uptake in lung cancer [33–35]. Sasaki et al. [36] reported that GLUT-1 overexpression evaluated by immunohistochemistry was significantly correlated with $\text{EFGR}$ or $\text{KRAS}$ mutation status, with overexpression in 18 (24%) of 76 EGFR $\text{m}^+$ lung cancers and 20 (67%) of 30 KRAS $\text{m}^+$ lung cancers. In our present patients, we found that the expression level of GLUT-1 was positively correlated with SUV$_{\text{max}}$, as were other genes related to glucose metabolism, namely HK-II, CAIX, and HIF-1$\alpha$ (Fig 3). This finding is consistent with previous reports [34, 37]. GO term analysis revealed that the glucose metabolism-related and the cell cycle-related genes were enriched among the down-regulated genes in EGFR $\text{m}^+$ adenocarcinomas, which supports our results for $^{18}$F-FDG PET, with lower levels of SUV$_{\text{max}}$. Notably, 4 of the glucose metabolism-related genes, GPI, G6PD, PKM2, and GAPDH and 5 of the cell cycle-related genes, ANLN, PTTG1, CIT, KPNA2, and CDC25A, were significantly down-regulated in EGFR $\text{m}^+$ adenocarcinomas, and showed a substantial correlation with SUV$_{\text{max}}$ (Fig 4). These likely comprise a common subset of the pathway underlying EGFR mutation and glucose metabolism.

Several limitations of our study warrant mention. First, it was conducted under a retrospective design in patients who required surgical resection, most for early stage disease. Accordingly, the selected cases might not have reflected the overall features of lung adenocarcinoma. Second, the sample size of KRAS $\text{m}^+$ tumors was too small to allow any firm conclusions. Although we found no significant relationship between $^{18}$F-FDG uptake and KRAS mutation status in lung adenocarcinoma and did not identify any genes specifically correlated with glucose metabolism in KRAS $\text{m}^+$ tumors, a conclusive answer to this question would require a larger sample size.

In summary, the probability of $\text{EGFR}$ mutation was inversely correlated with SUV$_{\text{max}}$. In contrast, the probability of $\text{KRAS}$ mutation was not correlated with SUV$_{\text{max}}$. Several genes associated with glucose metabolism or the cell cycle were specifically down-regulated in EGFR $\text{m}^+$ adenocarcinomas. These findings confirm that EGFR $\text{m}^+$ adenocarcinomas are biologically indolent with potentially lower levels of glucose metabolism than wild-type tumors.

**Table 5. Clinical studies of the role of $^{18}$F-FDG uptake on PET-CT scans in predicting $\text{EGFR}$ mutation status.**

| Author/year          | Ethnicity     | No. of patients | Histology | Stage          | SUV$_{\text{max}}$ | $\text{EGFR}$ mutation | Results $^*$          |
|----------------------|---------------|-----------------|-----------|----------------|---------------------|------------------------|-----------------------|
| Huang et al./2010    | Asian (Taiwanese) | 77              | Ad        | Clinical IIIB or IV | 49 (64%)       | SUV$_{\text{max}}$ > 9.5, EGFR $\text{m}^+$ 78% |
| Na et al./2010       | Asian (Korean) | 100             | 53 Ad, 47 non-Ad | Pathological I-IV | 21 (21%)       | SUV$_{\text{max}}$ > 9.2, EGFR $\text{m}^+$ 40% |
| Mak et al./2011      | White (88% of all) | 100             | 90 Ad, 10 non-Ad | Clinical I-IV       | 24 (24%)       | SUV$_{\text{max}}$ > 5.0, WT 96% |
| Ko et al./2014       | Asian (Taiwanese) | 132             | Ad        | Clinical I-IV | 69 (52%)       | SUV$_{\text{max}}$ > 6.0, EGFR $\text{m}^+$ 63% |
| Present study        | Asian (Japanese) | 734             | Ad        | Pathological I-IV | 334 (46%)      | SUV$_{\text{max}}$ ≤ 2.69, EGFR $\text{m}^+$ 62% |

$^*$ shows threshold SUV$_{\text{max}}$ and positive predictive value of EGFR mutation status.

Ad = adenocarcinoma; $\text{m}^+$ = mutation-positive; WT = wild-type.
**Author Contributions**

**Conceptualization:** KT KM MI HK.

**Data curation:** KT KI MF SO MI HK.

**Formal analysis:** KT KM MI HK WK MA.

**Funding acquisition:** KT YH.

**Investigation:** KT KM MI HK.

**Methodology:** KT KM HK.

**Project administration:** KT KS YH.

**Resources:** KT HK MI KI MF SO KS WK MA.

**Software:** KM HK.

**Supervision:** KS YH.

**Validation:** KM HK.

**Visualization:** KT KM HK.

**Writing – original draft:** KT KM HK.

**Writing – review & editing:** KS YH.

**References**

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380–8. Epub 2010/06/25. https://doi.org/10.1056/NEJMoaa0909530 PMID: 20573926

2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11(2):121–8. Epub 2009/12/22. https://doi.org/10.1016/S1470-2045(09)70364-X PMID: 20022809

3. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900–9. https://doi.org/10.1200/JCO.2005.02.857 PMID: 16043828

4. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol. 2003; 45(1):49–59. PMID: 12499064

5. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2000; 41(1):85–92. Epub 2000/01/27.

6. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vailiers E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(10):3837–44. Epub 2000/10/29.

7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The oncologist. 2002; 7 Suppl 4:2–8. Epub 2002/08/31.

8. Shiraki T, Kondo S, Katayama S, Waki K, Kasukawa T, Kawaji H, et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(26):15776–81. Epub 2003/12/10. PubMed Central PMCID: PMC37644. https://doi.org/10.1073/pnas.2136655100 PMID: 14663149

9. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. The American journal of surgical pathology. 2012; 36(6):895–9. Epub 2012/03/01. https://doi.org/10.1097/PAS.0b013e3182498f2b PMID: 22367298
26. Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of (18)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. European journal of nuclear medicine and molecular imaging. 2014; 41(10):1889–97. Epub 2014/05/24. https://doi.org/10.1007/s00259-014-2802-y PMID: 24852187

10. Andersson R, Gebhard C, Miguel-Escalada I, Hooi I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455–61. Epub 2014/03/29. https://doi.org/10.1038/nature12877 PMID: 24670763

11. Forrest AR, Kawaji H, Rehl M, Baille JK, de Hoon MJ, Lassmann T, et al. A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462–70. Epub 2014/03/29. https://doi.org/10.1038/nature13182 PMID: 24670764

12. Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drablos F, et al. Gene regulation. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (New York, NY). 2015; 347(6225):1010–4. Epub 2015/02/14.
27. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006; 11(3):190–8. Epub 2006/07/20. https://doi.org/10.1007/s10147-006-0583-4 PMID: 16850125

28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339–46. Epub 2005/03/03. https://doi.org/10.1093/jnci/dji055 PMID: 15741570

29. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006; 1(3):231–9. Epub 2007/04/06. PMID: 17409862

30. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2005; 46(2):267–73. Epub 2005/02/08.

31. Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, et al. Sequence and structure of a human glucose transporter. Science (New York, NY). 1985; 229(4717):941–5. Epub 1985/09/06.

32. Suganuma N, Segade F, Matsuoka K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU international. 2007; 99(5):1143–9. Epub 2007/04/18. https://doi.org/10.1111/j.1464-410X.2007.06765.x PMID: 17437443

33. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. European journal of nuclear medicine. 2000; 27(12):1778–85. Epub 2001/02/24.

34. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia (New York, NY). 2005; 7(4):369–79. Epub 2005/06/22. PubMed Central PMCID: PMC1501150.

35. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. European journal of cancer (Oxford, England: 1990). 2007; 43(9):1392–8. Epub 2007/05/22.

36. Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriya S, Yano M, et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Molecular medicine reports. 2012; 5(3):599–602. Epub 2011/12/28. https://doi.org/10.3892/mmr.2011.736 PMID: 22200795

37. Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2014; 83(2):197–204. Epub 2013/12/25.